Defective Ca2+ cycling as a key pathogenic mechanism of heart failure

Circulation Journal

Volumn 72, Issue SUPPL. A, 2008, Pages

  Yano, Masafumi ^a   Yamamoto, Takeshi ^a   Kobayashi, Shigeki ^a   Ikeda, Yasuhiro ^b   Matsuzaki, Masunori ^a  

^a YAMAGUCHI UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^b YAMAGUCHI UNIVERSITY SCHOOL OF MEDICINE   (Japan)

Author keywords

Calcium; Excitation contraction (E C) coupling; Heart failure; Sarcoplasmic reticulum

Indexed keywords

4 [3 (4 BENZYL 1 PIPERIDINYL)PROPIONYL] 2,3,4,5 TETRAHYDRO 7 METHOXY 1,4 BENZOTHIAZEPINE; ANGIOTENSIN RECEPTOR ANTAGONIST; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CALCIUM; CALCIUM CHANNEL; CALSEQUESTRIN; PHOSPHOLAMBAN; REGULATOR PROTEIN; RYANODINE RECEPTOR; SARCOPLASMIC RETICULUM CALCIUM TRANSPORTING ADENOSINE TRIPHOSPHATASE; SARCOPLASMIC RETICULUM CALCIUM TRANSPORTING ADENOSINE TRIPHOSPHATASE 2A; UNCLASSIFIED DRUG; VIRUS VECTOR;

ADRENERGIC SYSTEM; CALCIUM CELL LEVEL; CALCIUM METABOLISM; CALCIUM TRANSPORT; CARDIOMYOPATHY; CHANNEL GATING; DISEASE ACTIVITY; ENZYME INHIBITION; ENZYME PHOSPHORYLATION; EXCITATION CONTRACTION COUPLING; GENE MUTATION; GENE THERAPY; GENE TRANSFER; HEART ARRHYTHMIA; HEART CONTRACTION; HEART DEPOLARIZATION; HEART FAILURE; HEART MUSCLE CONTRACTILITY; HEART VENTRICLE HYPERTROPHY; MEMBRANE DEPOLARIZATION; MISSENSE MUTATION; NONHUMAN; PATHOPHYSIOLOGY; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN STRUCTURE; PROTEIN TARGETING; REVIEW; SARCOPLASMIC RETICULUM; SENSOR; ANIMAL; ELECTROPHYSIOLOGY; HEART; HEART MUSCLE; HUMAN; METABOLISM; MORTALITY;

ANIMALS; ARRHYTHMIAS, CARDIAC; CALCIUM; ELECTROPHYSIOLOGY; HEART; HEART FAILURE; HUMANS; MYOCARDIAL CONTRACTION; MYOCARDIUM; RYANODINE RECEPTOR CALCIUM RELEASE CHANNEL; SARCOPLASMIC RETICULUM; SYMPATHETIC NERVOUS SYSTEM;

EID: 52949119860     PISSN: 13469843     EISSN: 13474820     Source Type: Journal    
DOI: 10.1253/circj.CJ-08-0070     Document Type: Review

References (114)

1. Francis GS. Pathophysiology of chronic heart failure. Am J Med 2001; 110: 37S-46S.
2. Braunwald E, Bristow MR. Congestive heart failure: Fifty years of progress. Circulation 2000; 102(Suppl): IV-14 - IV-23.
3. Hasenfuss G, Pieske B. Calcium cycling in congestive heart failure. J Mol Cell Cardiol 2002; 34: 951-969.
4. 2+ handling in heart failure. J Clin Invest 2005; 15: 556-564.
5. 2+ content in isolated failing and nonfailing human myocardium. Circ Res 1999; 85: 38-46.
6. Hobai IA, O'Rourke B. Decreased sarcoplasmic reticulum calcium content is responsible for defective excitation-contraction coupling in canine heart failure. Circulation 2001; 103: 1577-1584.
7. Pogwizd SM, Schlotthauer K, Li L, Yuan W, Bers DM. Arrhythmogenesis and contractile dysfunction in heart failure: Roles of sodium-calcium exchange, inward rectifier potassium current, and residual beta-adrenergic responsiveness. Circ Res 2001; 88: 1159-1167.
8. Piacentino V 3rd, Weber CR, Chen X, Weisser-Thomas J, Margulies KB, Bers DM, et al. Cellular basis of abnormal calcium transients of failing human ventricular myocytes. Circ Res 2003; 92: 651-658.
9. 2+ channels and ryanodine receptors in heart cells. Nature 2001; 410: 592-596.
10. 2+) release units and couplons in skeletal and cardiac muscles. Biophys J 1999; 77: 1528-1539.
11. Bers DM. Macromolecular complexes regulating cardiac ryanodine receptor function (Review). J Mol Cell Cardiol 2004; 37: 417-429.
12. Fabiato A. Calcium-induced release of calcium from the cardiac sarcoplasmic reticulum (Review). Am J Physiol 1983; 245: C1-C14.
13. Bers DM. Cardiac excitation-contraction coupling. Nature 2002; 415: 198-205.
14. Hasenfuss G. Alterations of calcium-regulatory proteins in heart failure. Cardiovasc Res 1998; 37: 279-289.
15. Shröder F, Handrock R, Beuckelmann DJ, Hirt S, Hullin R, Priebe L, et al. Increased availability and open probability of single L-type calcium channels from failing compared with nonfailing human ventricle. Circulation 1998; 98: 969-976.
16. 2+ channel density and regulation are altered in failing human ventricular myocytes and recover after support with mechanical assist devices. Circ Res 2002; 91: 517-524.
17. 2+ sparks, and local control of excitation-contraction coupling in normal heart muscle. Circ Res 1999; 85: 770-776.
18. Piot C, Lemaire S, Albat B, Seguin J, Nargeot J, Richard S. High frequency-induced upregulation of human cardiac calcium currents. Circulation 1996; 93: 120-128.
19. Barrere-Lemaire S, Piot C, Leclercq F, Nargeot J, Richard S. Facilitation of L-type calcium currents by diastolic depolarization in cardiac cells: Impairment in heart failure. Cardiovasc Res 2000; 47: 336-349.
20. 2+ channels in canine tachycardia-induced heart failure. Cardiovasc Res 2001; 49: 298-307.
21. Gomez AM, Valdivia HH, Cheng H, Lederer MR, Santana LF, Cannell MB, et al. Defective excitation-contraction coupling in experimental cardiac hypertrophy and heart failure. Science 1997; 276: 800-806.
22. Lindner M, Erdmann E, Beuckelmann DJ. Calcium content of the sarcoplasmic reticulum in isolated ventricular myocytes from patients with terminal heart failure. J Mol Cell Cardiol 1998; 30: 743-749.
23. 2+ leak through ryanodine receptor in heart failure. Circulation 2000; 102: 2131-2136.
24. 2+ release in heart failure. Cardiovasc Res 2000; 48: 323-331.
25. 2+ release from cardiac sarcoplasmic reticulum in tachycardia-induced heart failure. Cardiovasc Res 1999; 44: 146-155.
26. Marx SO, Gaburjakova J, Gaburjakova M, Henrikson C, Ondrias K, Marks AR. Coupled gating between cardiac calcium release channels (ryanodine receptors). Circ Res 2001; 88: 1151-1158.
27. 2+ management in cardiac myocytes. Ann NY Acad Sci 2004; 1015: 28-38.
28. Bers DM. Macromolecular complexes regulating cardiac ryanodine receptor function. J Mol Cell Cardiol 2004; 37: 417-429.
29. Marx SO, Reiken S, Hisamatsu Y, Jayaraman T, Burkhoff D, Rosemblit N, et al. PKA phosphorylation dissociates FKBP12.6 from the calcium release channel (ryanodine receptor): Defective regulation in failing hearts. Cell 2000; 101: 365-376.
30. Takeshima H, Nishimura S, Matsumoto T, Ishida H, Kangawa K, Minamino N, et al. Primary structure and expression from complementary DNA of skeletal muscle ryanodine receptor. Nature 1989; 339: 439-445.
31. 2+ release channel (ryanodine receptor) of rabbit cardiac muscle sarcoplasmic reticulum. J Biol Chem 1990; 265: 13472-13483.
32. Hakamata Y, Nakai J, Takeshima H, Imoto K. Primary structure and distribution of a novel ryanodine receptor/calcium release channel from rabbit brain. FEBS Lett 1992; 312: 229-235.
33. Franzini-Armstrong C, Jorgensen AO. Structure and development of E-C coupling units in skeletal muscle. Annu Rev Physiol 1994; 56: 509-534.
34. 2+ release channel (ryanodine receptor) of skeletal muscle sarcoplasmic reticulum. J Biol Chem 1990; 265: 2244-2256.
35. 2+ release channel of skeletal muscle sarcoplasmic reticulum (RyR1). Proc Natl Acad Sci USA 2002; 99: 16725-16730.
36. Yano M, Yamamoto T, Ikemoto N, Matsuzaki M. Abnormal ryanodine receptor function in heart failure (Review). Pharmacol Ther 2005; 107: 377-391.
37. Zhang L, Kelley J, Schmeisser G, Kobayashi YM, Jones LR. Complex formation between junctin, triadin, calsequestrin, and the ryanodine receptor: Proteins of the cardiac junctional sarcoplasmic reticulum membrane. J Biol Chem 1997; 272: 23389-23397.
38. Marks AR. Ryanodine receptors/calcium release channels in heart failure and sudden cardiac death (Review). J Mol Cell Cardiol 2001; 33: 615-624.
39. Lehnart SE, Wehrens XH, Reiken S, Warrier S, Belevych AE, Harvey RD, et al. Phosphodiesterase 4D deficiency in the ryanodine-receptor complex promotes heart failure and arrhythmias. Cell 2005; 123: 25-35.
40. Doi M, Yano M, Kobayashi S, Kohno M, Tokuhisa T, Okuda S, et al. Propranolol prevents the development of heart failure by restoring FKBP12.6-mediated stabilization of ryanodine receptor. Circulation 2002; 105: 1374-1379.
41. 2+-release channel (ryanodine receptor) does not dissociate 12.6-kDa FK506-binding protein (FKBP12.6). Circ Res 2004; 94: 487-495.
42. Stange M, Xu L, Balshaw D, Yamaguchi N, Meissner G. Characterization of recombinant skeletal muscle (Ser-2843) and cardiac muscle (Ser-2809) ryanodine receptor phosphorylation mutants. J Biol Chem 2003; 278: 51693-51702.
43. Xiao B, Zhong G, Obayashi M, Yang D, Chen K, Walsh MP, et al. Ser-2030, but not Ser-2808, is the major phosphorylation site in cardiac ryanodine receptors responding to protein kinase A activation upon beta-adrenergic stimulation in normal and failing hearts. Biochem J 2006; 396: 7-16.
44. 2+ release. J Biol Chem 2007; 282: 30256-30264.
45. 2+ release (SOICR). Proc Natl Acad Sci USA 2004; 101: 13062-13067.
46. Wehrens XH, Lehnart SE, Reiken S, Vest JA, Wronska A, Marks AR. Ryanodine receptor/calcium elease channel PKA phosphorylation: A critical mediator of heart failure progression. Proc Natl Acad Sci USA 2006; 103: 511-518.
47. Benkusky NA, Weber CS, Scherman JA, Farrell EF, Hacker TA, John MC, et al. Intact beta-adrenergic response and unmodified progression toward heart failure in mice with genetic ablation of a major protein kinase A phosphorylation site in the cardiac ryanodine receptor. Circ Res 2007; 101: 819-829.
48. Lehnart S, Marks AR. Regulation of ryanodine receptors in the heart. Circ Res 2007; 101: 746-749.
49. Zhang T, Maier LS, Dalton ND, Miyamoto S, Ross J Jr, Bers DM, et al. The deltaC isoform of CaMKII is activated in cardiac hypertrophy and induces dilated cardiomyopathy and heart failure. Circ Res 2003; 92: 912-919.
50. 2+ release. Circ Res 2003; 92: 904-911.
51. Li Y, Kranias EG, Mignery GA, Bers DM. Protein kinase A phos-phorylation of the ryanodine receptor does not affect calcium sparks in mouse ventricular myocytes. Circ Res 2002; 90: 309-316.
52. 2+/calmodulin-dependent protein kinase II phosphorylation of ryanodine receptor does affect calcium sparks in mouse ventricular myocytes. Circ Res 2006; 99: 398-406.
53. 2+ leak in heart failure. Circ Res 2005; 97: 1314-1322.
54. Gaburjakova M, Gaburjakova J, Reiken S, Huang F, Marx SO, Rosemblit N, et al. FKBP12 binding modulates ryanodine receptor channel gating. J Biol Chem 2001; 276: 16931-16935.
55. 2+ release channel (ryanodine receptor). J Biol Chem 2003; 278: 3786-3792.
56. Zhang J, Liu Z, Masumiya H, Wang R, Jiang D, Li F, et al. Three-dimensional localization of divergent region 3 of the ryanodine receptor to the clamp-shaped structures adjacent to the FKBP binding sites. J Biol Chem 2003; 278: 14211-14218.
57. Zissimopoulos S, Lai FA. Interaction of FKBP12.6 with the cardiac ryanodine receptor C-terminal domain. J Biol Chem 2005; 280: 5475-5485.
58. Meng X, Xiao B, Cai S, Huang X, Li F, Bolstad J, et al. Three-dimensional localization of serine 2808, a phosphorylation site in cardiac ryanodine receptor. J Biol Chem 2007; 282: 25929-25939.
59. Priori SG, Napolitano C, Tiso N, Memmi M, Vignati G, Bloise R, et al. Mutations in the cardiac ryanodine receptor gene (hRyR2) underlie catecholaminergic polymorphic ventricular tachycardia. Circulation 2001; 103: 196-200.
60. Laitinen PJ, Brown KM, Piippo K, Swan H, Devaney JM, Brahmbhatt B, et al. Mutations of the cardiac ryanodine receptor (RyR2) gene in familial polymorphic ventricular tachycardia. Circulation 2001; 103: 485-490.
61. Tiso N, Stephan DA, Nava A, Bagattin A, Devaney JM, Stanchi F, et al. Identification of mutations in the cardiac ryanodine receptor gene in families affected with arrhythmogenic right ventricular cardiomyopathy type 2 (ARVD2). Hum Mol Genet 2001; 10: 189-194.
62. Ikemoto N, Yamamoto T. Regulation of calcium release by interdomain interaction within ryanodine receptors. Front Biosci 2002; 7: d671-d683.
63. Yamamoto T, Ikemoto N. Peptide probe study of the critical regulatory domain of the cardiac ryanodine receptor. Biochem Biophys Res Commun 2002; 291: 1102-1108.
64. Liu Z, Wang R, Zhang J, Chen SR, Wagenknecht T. Localization of a disease-associated mutation site in the three-dimensional structure of the cardiac muscle ryanodine receptor. J Biol Chem 2005; 280: 37941-37947.
65. Oda T, Yano M, Yamamoto T, Tokuhisa T, Okuda S, Doi M, et al. Defective regulation of interdomain interactions within the ryanodine receptor plays a key role in the pathogenesis of heart failure. Circulation 2005; 111: 3400-3410.
66. 2+ release channel dysfunction. Circ Res 2006; 98: 88-97.
67. Thomas NL, George CH, Lai FA. Functional heterogeneity of ryanodine receptor mutations associated with sudden cardiac death. Cardiovasc Res 2004; 64: 52-60.
68. 2+ binding effects on protein conformation and protein interactions of canine cardiac calsequestrin. J Biol Chem 1988; 263: 1376-1381.
69. Györke I, Hester N, Jones LR, Györke S. The role of calsequestrin, triadin, and junctin in conferring cardiac ryanodine receptor responsiveness to luminal calcium. Biophys J 2004; 86: 2121-2128.
70. Lahat H, Pras E, Eldar M. A missense mutation in CASQ2 is associated with autosomal recessive catecholamine-induced polymorphic ventricular tachycardia in Bedouin families from Israel. Ann Med 2004; 36: 87-91.
71. Terentyev D, Nori A, Santoro M, Viatchenko-Karpinski S, Kubalova Z, Gyorke I, et al. Abnormal interactions of calsequestrin with the ryanodine receptor calcium release channel complex linked to exercise-induced sudden cardiac death. Circ Res 2006; 98: 1151-1158.
72. di Barletta MR, Viatchenko-Karpinski S, Nori A, Memmi M, Terentyev D, Turcato F, et al. Clinical phenotype and functional characterization of CASQ2 mutations associated with catecholaminergic polymorphic ventricular tachycardia. Circulation 2006; 114: 1012-1019.
73. Postma AV, Denjoy I, Hoorntje TM, Lupoglazoff JM, Da Costa A, Sebillon P, et al. Absence of calsequestrin 2 causes severe forms of catecholaminergic polymorphic ventricular tachycardia. Circ Res 2002; 91: e21-e26.
74. 2+ release, and catecholaminergic polymorphic ventricular tachycardia. J Clin Invest 2006; 116: 2510-2520.
75. Song L, Alcalai R, Arad M, Wolf CM, Toka O, Conner DA, et al. Calsequestrin 2 (CASQ2) mutations increase expression of calreticulin and ryanodine receptors, causing catecholaminergic polymorphic ventricular tachycardia. J Clin Invest 2007; 117: 1814-1823.
76. 2+ and phosphorylation. Biophys J 2005; 88: 3444-3454.
77. Pieske B, Maier LS, Piacentino V 3rd, Weisser J, Hasenfuss G, Houser S. Rate dependence of [Na+]i and contractility in nonfailing and failing human myocardium. Circulation 2002; 106: 447-453.
78. Despa S, Islam MA, Weber CR, Pogwizd SM, Bers DM. Intracellular Na(+) concentration is elevated in heart failure but Na/K pump function is unchanged. Circulation 2002; 105: 2543-2548.
79. Pieske B, Houser SR. [Na+]i handling in the failing human heart (Review). Cardiovasc Res 2003; 57: 874-886.
80. Limas CJ, Olivari MT, Goldenberg IF, Levine TB, Benditt DG, Simon A. Calcium uptake by cardiac sarcoplasmic reticulum in human dilated cardiomyopathy. Cardiovasc Res 1987; 21: 601-605.
81. 2+)-sensitivity of SERCA 2a in failing human myocardium due to reduced serin-16 phospholamban phos-phorylation. J Mol Cell Cardiol 1999; 31: 479-491.
82. Sande JB, Sjaastad I, Hoen IB, Bokenes J, Tonnessen T, Holt E, et al. Reduced level of serine16 phosphorylated phospholamban in the failing rat myocardium: A major contributor to reduced SERCA2 activity. Cardiovasc Res 2002; 53: 382-391.
83. Bohm M, Reiger B, Schwinger RH, Erdmann E. cAMP concentrations, cAMP dependent protein kinase activity, and phospholamban in non-failing and failing myocardium. Cardiovasc Res 1994; 28: 1713-1719.
84. 2+)/calmodulin-dependent protein kinase is altered in heart failure. Circ Res 2000; 86: 596-605.
85. 2+- calmodulin-dependent protein kinase activity and expression in LV myocardium of dogs with heart failure. Am J Physiol Heart Circ Physiol 2003; 284: H876-H883.
86. Neumann J, Eschenhagen T, Jones LR, Linck B, Schmitz W, Scholz H, et al. Increased expression of cardiac phosphatases in patients with end-stage heart failure. J Mol Cell Cardiol 1997; 29: 265-272.
87. Huang B, Wang S, Qin D, Boutjdir M, El-Sherif N. Diminished basal phosphorylation level of phospholamban in the postinfarction remodeled rat ventricle: Role of beta-adrenergic pathway, G(i) protein, phosphodiesterase, and phosphatases. Circ Res 1999; 85: 848-855.
88. Gupta RC, Mishra S, Rastogi S, Imai M, Habib O, Sabbah HN. Cardiac SR-coupled PP1 activity and expression are increased and inhibitor 1 protein expression is decreased in failing hearts. Am J Physiol Heart Circ Physiol 2003; 285: H2373-H2381.
89. Gupta RC, Mishra S, Yang XP, Sabbah HN. Reduced inhibitor 1 and 2 activity is associated with increased protein phosphatase type 1 activity in left ventricular myocardium of one-kidney, one-clip hypertensive rats. Mol Cell Biochem 2005; 269: 49-57.
90. Carr AN, Schmidt AG, Suzuki Y, del Monte F, Sato Y, Lanner C, et al. Type 1 phosphatase, a negative regulator of cardiac function. Mol Cell Biol 2002; 22: 4124-4135.
91. El-Armouche A, Pamminger T, Ditz D, Zolk O, Eschenhagen T. Decreased protein and phosphorylation level of the protein phosphatase inhibitor-1 in failing human hearts. Cardiovasc Res 2004; 61: 87-93.
92. Yamada M, Ikeda Y, Yano M, Yoshimura K, Nishino S, Aoyama H, et al. Inhibition of protein phosphatase 1 by inhibitor-2 gene delivery ameliorates heart failure progression in genetic cardiomyopathy. Faseb J 2006; 20: 1197-1199.
93. Pass JM, Gao J, Jones WK, Wead WB, Wu X, Zhang J, et al. Enhanced PKCβ II translocation and PKC-β II-RACK1 interactions in PKCe-induced heart failure: A role for RACK1. Am J Physiol 2001; 281: H2500-H2510.
94. Braz JC, Gregory K, Pathak A, Zhao W, Sahin B, Klevitsky R, et al. PKC-alpha regulates cardiac contractility and propensity toward heart failure. Nat Med 2004; 10: 248-254.
95. Reiken S, Wehrens XH, Vest JA, Barbone A, Klotz S, Mancini D, et al. Beta-blockers restore calcium release channel function and improve cardiac muscle performance in human heart failure. Circulation 2003; 107: 2459-2466.
96. Okuda S, Yano M, Doi M, Oda T, Tokuhisa T, Kohno M, et al. Valsartan restores sarcoplasmic reticulum function with no appreciable effect on resting cardiac function in pacing-induced heart failure. Circulation 2004; 109: 911-919.
97. Yano M, Kobayashi S, Kohno M, Doi M, Tokuhisa T, Okuda S, et al. FKBP12.6-mediated stabilization of calcium-release channel (ryanodine receptor) as a novel therapeutic strategy against heart failure. Circulation 2003; 107: 477-484.
98. Wehrens XH, Lehnart SE, Reiken SR, Deng SX, Vest JA, Cervantes D, et al. Protection from cardiac arrhythmia through ryanodine receptor-stabilizing protein calstabin2. Science 2004; 304: 292-296.
99. Yamamoto T, Yano M, Xu X, Uchinoumi H, Tateishi H, Mochizuki M, et al. Identification of target domains of the cardiac ryanodine receptor to correct channel disorder in failing hearts. Circulation 2008; 117: 762-772.
100. Liu N, Colombi B, Memmi M, Zissimopoulos S, Rizzi N, Negri S, et al. Arrhythmogenesis in catecholaminergic polymorphic ventricular tachycardia: Insights from a RyR2 R4496C knock-in mouse model. Circ Res 2006; 99: 292-298.
101. Yano M, Okuda S, Oda T, Tokuhisa T, Tateishi H, Mochizuki M, et al. Correction of defective interdomain interaction within ryanodine receptor by antioxidant is a new therapeutic strategy against heart failure. Circulation 2005; 112: 3633-3643.
102. 2+ leak via stabilization of ryanodine receptor in heart failure. J Am Coll Cardiol 2007; 49: 1722-1732.
103. Miyamoto MI, del Monte F, Schmidt U, DiSalvo TS, Kang ZB, Matsui T, et al. Adenoviral gene transfer of SERCA2a improves left-ventricular function in aortic-banded rats in transition to heart failure. Proc Natl Acad Sci USA 2000; 97: 793-798.
104. 2+)-ATPase in a rat model of heart failure. Circulation 2001; 104: 1424-1429.
105. 2+ ATPase gene in the heart of transgenic mice accelerates calcium transients and cardiac relaxation. J Clin Invest 1997; 100: 380-389.
106. 2+-ATPase increases cardiac contractility in transgenic mouse hearts. Circ Res 1998; 83: 1205-1214.
107. 2+)-ATPase improves myocardial contractility in diabetic cardiomyopathy. Diabetes 2002; 51: 1166-1171.
108. Calcium Up-Regulation by Percutaneous Administration of Gene Therapy In Cardiac Disease (CUPID Trial) http://www.celladon.net http://www.celladon.net/ press_may1707.php
109. Minamisawa S, Hoshijima M, Chu G, Ward CA, Frank K, Gu Y, et al. Chronic phospholamban-sarcoplasmic reticulum calcium ATPase interaction is the critical calcium cycling defect in dilated cardio-myopathy. Cell 1999; 99: 313-322.
110. Hoshijima M, Ikeda Y, Iwanaga Y, Minamisawa S, Date MO, Gu Y, et al. Chronic suppression of heart-failure progression by a pseudo-phosphorylated mutant of phospholamban via in vivo cardiac rAAV gene delivery. Nat Med 2002; 8: 864-871.
111. Iwanaga Y, Hoshijima M, Gu Y, Iwatate M, Dieterle T, Ikeda Y, et al. Chronic phospholamban inhibition prevents progressive cardiac dysfunction and pathological remodeling after infarction in rats. J Clin Invest 2004; 113: 727-736.
112. Delling U, Sussman MA, Molkentin JD. Re-evaluating sarcoplasmic reticulum function in heart failure. Nat Med 2000; 6: 942-943.
113. Song Q, Schmidt AG, Hahn HS, Carr AN, Frank B, Pater L, et al. Rescue of cardiomyocyte dysfunction by phospholamban ablation does not prevent ventricular failure in genetic hypertrophy. J Clin Invest 2003; 111: 859-867.
114. Kirchhefer U, Baba HA, Boknik P, Breeden KM, Mavila N, Bruchert N, et al. Enhanced cardiac function in mice overexpressing protein phosphatase Inhibitor-2. Cardiovasc Res 2005; 68: 98-108.